2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-121517
    URB754 86672-58-4 98%
    URB754 is a potent inhibitor of the endocannabinoid-deactivating enzyme monoacylglycerol lipase (MGL) with an IC50 of 200 nM.
    URB754
  • HY-121557
    OMDM-1 616884-62-9 98.05%
    OMDM-1 is a potent, selective and metabolically stable inhibitor of anandamide cellular uptake (ACU), with a Ki of 2.4 μM.
    OMDM-1
  • HY-121558
    JP104 887264-45-1 98%
    JP104, a aryl carbamate, is an irreversible FAAH inhibitor with a pIC50 of ~8.
    JP104
  • HY-121562
    SB 714786 584555-10-2 98%
    SB 714786 is a potent and selective 5-hydroxytryptamine 1D (5-HT1D) receptor antagonist. It was developed from the previously reported series of dual 5-HT1 selective 5-hydroxytryptamine reuptake inhibitors (5HT1-SSRIs). SB 714786 is the first reported highly potent and selective 5-HT1D receptor antagonist, providing an extremely useful pharmacological tool for further understanding the role of 5-HT1 receptor subtypes. It has no or very low intrinsic activity against all three receptors. SB 714786 has pKi values of 6.5, 6.7, 9.1 and 6.5 for 5-HT1A, 5-HT1B, 5-HT1D and SerT receptors, respectively, showing high selectivity for 5-HT1D receptors. These properties make SB 714786 a potential tool compound for studying the function of 5-HT1D receptors and the treatment of related diseases.
    SB 714786
  • HY-121578
    Agaridoxin 58298-77-4 98%
    Agaridoxin (GDHB) is a blocker of catecholamine and adrenergic alpha-type receptors isolated from mushrooms. Agaridoxin activates adenylyl cyclase in rat hypothalamic membrane granules in the presence of guanosyl imide diphosphate (Gpp(NH)p).
    Agaridoxin
  • HY-121595
    5,5-Diphenylbarbituric acid 21914-07-8
    5,5-Diphenylbarbituric acid is an organic compound belonging to the derivatives of barbituric acid. 5,5-Diphenylbarbituric acid can be used for seizure study.
    5,5-Diphenylbarbituric acid
  • HY-121602
    DSP 4 free base 62078-98-2 98%
    DSP 4 Free base is a selective neurotoxin that targets noradrenergic neurons in the locus coeruleus noradrenergic system. DSP 4 Free base possesses the unique ability to cross the blood–brain barrier. DSP 4 Free base cyclizes to form a reactive aziridinium derivative that accumulates in noradrenergic neurons.
    DSP 4 free base
  • HY-121603
    Bornaprine 20448-86-6 98%
    Bornaprine is an anticholinergic agent that can be used in the study of parkinsonism. Bornaprine shows a pA2 value of 7.27.
    Bornaprine
  • HY-121609
    Pholedrine 370-14-9 98%
    Pholedrine, the main metabolite of methamphetamine, is an indirectly acting sympathomimetic amine. Pholedrine is a cardiovascular agent exerting hypertensive and adrenergic effects. Pholedrine can produce mydriatic response and allow localization of the site of the interruption in the oculosympathetic pathway. Pholedrine can be used as a topical eye drop and a diagnostic agent for use in Horner's syndrome.
    Pholedrine
  • HY-121616
    (R)-SLV 319 656827-86-0 98%
    (R)-SLV 319 is a potent and selective cannabinoid receptor 1 (CB1) antagonist with a Ki value of 894 nM. (R)-SLV 319 is a dextrorotatory counterpart of SLV 319
    (R)-SLV 319
  • HY-121637
    IDFP 615250-02-7 98%
    IDFP (iso-Prdodecylfluorophosphonate) is a chemical affinity probe for the cannabinoid CB1 receptor.
    IDFP
  • HY-121644
    Viminol 21363-18-8 98%
    Viminol is a centrally acting analgesic agent. Viminol also shows antitussive activity.
    Viminol
  • HY-121650
    ADTN 53463-78-8 98%
    ADTN is a dopamine receptor agonist that has the activity of promoting dopamine neurotransmission. ADTN can be used to increase the release of neurotransmitters, thereby improving dopamine-related physiological functions. ADTN's potential applications include inhibiting mental illness and improving cognitive function.
    ADTN
  • HY-121670
    Ambenoxan 2455-84-7 98%
    Ambenoxan is a central nervous system-acting skeletal muscle relaxant that is effective in mice, rats, rabbits, dogs, and monkeys without loss of the righting reflex. It has no peripheral neuromuscular blocking effects and significantly reduces or eliminates decerebrate rigidity in rabbits, but does not antagonize the effects of strychnine, leptazol, or tremorine. Like other central nervous system depressants, ambenoxan prolongs sleep duration with hexobarbitone, but it has no local anesthetic effects. In anesthetized cats, the agent lowers blood pressure and reduces the pressor response to epinephrine, but has no effect on norepinephrine.
    Ambenoxan
  • HY-121671
    TBTC 213192-26-8 98%
    TBTC is a selective agonist with the activity of improving behavioral deficits in Alzheimer's disease model mice. TBTC can effectively activate the heterodimerization of RXRα with LXRα or PPARγ. TBTC stimulates the expression of apoE, ABCA1, and ABCG1 genes and reduces Aβ content in cells and animal models.
    TBTC
  • HY-121679
    COX-2-IN-50 1242169-24-9 98%
    COX-2-IN-50 is a water-soluble COX-2 inhibitor with significant analgesic activity. The solubility of COX-2-IN-50 in water reaches 20.3 mg/mL, far exceeding the 1.6 μg/mL of its precursor compound PC407. COX-2-IN-50 demonstrates good biocompatibility and is suitable for the development of injectable dosage forms. COX-2-IN-50 has proven its analgesic effect in vivo and shows potential application value.
    COX-2-IN-50
  • HY-121685
    Tipepidine 5169-78-8 98%
    Tipepidine reversibly inhibits dopamine (DA) D2 receptor-mediated GIRK currents (IDA(GIRK)) with an IC50 of 7.0 μM. Tipepidine subsequently activates VTA dopamine neuron. Tipepidine, a non-narcotic antitussive, exerts an antidepressant-like effect.
    Tipepidine
  • HY-121704
    SR 57227A free base 77145-51-8 98%
    SR 57227A Free base is a highly selective compound for both peripheral and central 5-HT3 receptors and acts as an inhibitor of NMDA receptor-mediated responses in rat cortical pyramidal cells, demonstrating antidepressant-like effects in rats while reducing isolation-induced aggressive behavior.
    SR 57227A free base
  • HY-121711
    5-OH-HxMF 1176-88-1 98%
    5-OH-HxMF is a hydroxylated polymethoxyflavone that has anti-inflammatory, anticancer, neurotrophic and neuroprotective activities.
    5-OH-HxMF
  • HY-121751
    A 643C 65822-42-6 98%
    A 643C is an investigative antidepressant.
    A 643C
Cat. No. Product Name / Synonyms Application Reactivity